Incyte Corporation (INCY) Price Target Cut to $162.00 by Analysts at BMO Capital Markets

Incyte Corporation (NASDAQ:INCY) had its price objective reduced by BMO Capital Markets from $163.00 to $162.00 in a report released on Thursday, October 26th. They currently have an outperform rating on the biopharmaceutical company’s stock.

A number of other equities research analysts have also commented on the stock. Raymond James Financial, Inc. raised shares of Incyte Corporation from a market perform rating to an outperform rating and set a $159.00 price objective on the stock in a research note on Monday, September 11th. J P Morgan Chase & Co reissued a buy rating and set a $149.00 target price on shares of Incyte Corporation in a research note on Thursday, August 31st. Oppenheimer Holdings, Inc. reissued a hold rating and set a $135.00 target price on shares of Incyte Corporation in a research note on Thursday, August 31st. Barclays PLC upped their price objective on shares of Incyte Corporation from $135.00 to $185.00 and gave the stock an overweight rating in a report on Tuesday, July 4th. Finally, Argus reiterated a buy rating and issued a $150.00 target price on shares of Incyte Corporation in a report on Wednesday, September 13th. Seven equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average price target of $144.98.

Incyte Corporation (INCY) opened at $104.76 on Thursday. Incyte Corporation has a 12-month low of $98.49 and a 12-month high of $153.15. The company has a current ratio of 4.82, a quick ratio of 4.81 and a debt-to-equity ratio of 0.01.

Incyte Corporation (NASDAQ:INCY) last released its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.06 by $0.11. Incyte Corporation had a negative net margin of 10.90% and a negative return on equity of 12.91%. The business had revenue of $381.50 million during the quarter, compared to analysts’ expectations of $360.34 million. During the same period in the prior year, the company earned $0.19 EPS. The firm’s quarterly revenue was up 41.6% compared to the same quarter last year. analysts forecast that Incyte Corporation will post -1.3 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be viewed at https://ledgergazette.com/2017/11/13/incyte-corporation-incy-pt-lowered-to-162-00.html.

In other news, insider David W. Gryska sold 3,915 shares of the stock in a transaction that occurred on Thursday, November 2nd. The stock was sold at an average price of $105.63, for a total transaction of $413,541.45. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Bros. Advisors Lp Baker bought 100,000 shares of the stock in a transaction dated Friday, September 8th. The shares were purchased at an average price of $132.00 per share, with a total value of $13,200,000.00. The disclosure for this purchase can be found here. Insiders sold a total of 102,062 shares of company stock valued at $12,652,893 over the last 90 days. 17.70% of the stock is currently owned by corporate insiders.

A number of large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its holdings in Incyte Corporation by 11.1% during the 2nd quarter. Vanguard Group Inc. now owns 17,125,542 shares of the biopharmaceutical company’s stock valued at $2,156,276,000 after buying an additional 1,709,685 shares during the period. Capital International Investors increased its stake in Incyte Corporation by 4.0% in the second quarter. Capital International Investors now owns 6,407,197 shares of the biopharmaceutical company’s stock worth $806,730,000 after purchasing an additional 246,134 shares during the period. BB Biotech AG increased its stake in Incyte Corporation by 0.7% in the second quarter. BB Biotech AG now owns 3,514,822 shares of the biopharmaceutical company’s stock worth $442,551,000 after purchasing an additional 25,000 shares during the period. Matrix Capital Management Company LP increased its stake in Incyte Corporation by 28.3% in the second quarter. Matrix Capital Management Company LP now owns 1,796,716 shares of the biopharmaceutical company’s stock worth $226,225,000 after purchasing an additional 396,716 shares during the period. Finally, UBS Asset Management Americas Inc. increased its stake in Incyte Corporation by 10.7% in the second quarter. UBS Asset Management Americas Inc. now owns 1,636,035 shares of the biopharmaceutical company’s stock worth $205,993,000 after purchasing an additional 158,574 shares during the period. Institutional investors own 89.53% of the company’s stock.

About Incyte Corporation

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Analyst Recommendations for Incyte Corporation (NASDAQ:INCY)

Receive News & Ratings for Incyte Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply